ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens - ACROFAN USA

Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancerBased on groundbreaking DESTINY-Breast03 results in which ENHERTU demonstrated a 72% reduction in the risk of disea…

• Approval broadens indication for Daiichi Sankyo and AstraZenecas ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancer
• Based on groundbreaking DESTINY-B… [+14196 chars]
  full article...